← Back to all trials
Recruiting
NCT07059767
Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge
Conditions: Asthma (Diagnosis)
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 50
Sponsor: Ethris GmbH
Location: Imperial College Healthcare NHS Trust London
Summary
A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge
Eligibility Criteria
Inclusion Criteria:
1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
2. Participants aged ≥18 and ≤65 years at the time of obtaining informed consent.
3. Diagnosis of clinical asthma (\>12% reversibility following short acting beta 2 agonist (SABA) treatment or PC20 methacholine challenge of \5 year pack history; current vapers may be included if willing to stop prior to Baseline.
Source: ClinicalTrials.gov (NCT07059767). StuddyBuddy aggregates publicly available trial information.
